Article

T cell responses to SARS-CoV-2 vaccination in people with multiple sclerosis differ between disease-modifying therapies

2022-08-25

Abstract excerpt

Immune responses in people with multiple sclerosis (pwMS) on disease-modifying therapies (DMTs) have been of significant interest throughout the COVID-19 pandemic. Lymphocyte-targeting immunotherapies including anti-CD20 treatments and sphingosine-1-phosphate receptor (S1PR) modulators attenuate antibody responses after vaccination. Evaluation of cellular responses after vaccination is therefore of particular impo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8b324c8b-ddaa-52f5-8e8c-d8ba8b450fca
DOI: 10.1101/2022.08.25.22279202

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

T cell responses to SARS-CoV-2 vaccination in people with multiple sclerosis differ between disease-modifying therapiesDOI 10.1101/2022.08.25.22279202Read

Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20 treated patients with multiple sclerosis after three or four COVID-19 vaccinationsSemantic proximity Read

Immune profiling of COVID-19 vaccine responses in people with multiple sclerosis on B cell-depleting therapySemantic proximity Read

Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapySemantic proximity Read

Preserved T-cell Response in anti-CD20 Treated Multiple Sclerosis Patients Following SARS-CoV-2 VaccinationSemantic proximity Read

Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapySemantic proximity Read

Durable T cell immunity to COVID-19 vaccines in MS patients on B cell depletion therapySemantic proximity Read

B- and T-cell Specific Responses to Vaccination against SARS-CoV-2 in Anti-CD20 Treated Patients with Relapsing-Remitting or Progressive Form of Multiple Sclerosis Reveal Immunosenescent FeaturesSemantic proximity Read

Effect of different disease-modifying therapies on humoral response to BNT162b2 vaccine in Sardinian multiple sclerosis patientsSemantic proximity Read

The Impact of Sphinogosine-1-Phosphate Receptor Modulators on COVID-19 and SARS-CoV-2 VaccinationSemantic proximity Read

Response to COVID-19 booster vaccinations in seronegative people with MSSemantic proximity Read

Omicron-specific cytotoxic T-cell responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-treated multiple sclerosis patientsSemantic proximity Read

Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple SclerosisSemantic proximity Read